Pulmonary Hypertension (PH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Pulmonary Hypertension (PH) Market Outlook

Thelansis’s “Pulmonary Hypertension (PH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Hypertension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pulmonary Hypertension (PH) Overview

Pulmonary hypertension (PH) is elevated lung blood pressure from various causes, distinct from systemic hypertension, affecting the entire body. There are five categorized groups of pulmonary hypertension, each linked to specific causes, necessitating varied treatments. Despite these differences, all forms of pulmonary hypertension pose serious and potentially life-threatening risks. Pulmonary hypertension (PH) is characterized as a hemodynamic state rather than a standalone diagnosis, with a resting mean pulmonary artery pressure (PAPm) of ≥ 25 mm Hg. Within this category, pulmonary arterial hypertension represents a specific subgroup defined by unique hemodynamic features. These include precapillary pulmonary hypertension, elevated pulmonary vascular resistance (PVR), PAPm ≥ 25 mm Hg, normal pulmonary arterial wedge pressure (PAWP) ≤ 15 mm Hg, and PVR >240 dyn × s × cm-5 in individuals of any age, be they children or adults. Primary causes of pulmonary hypertension often involve left heart disease and lung disease. Recognizable symptoms include escalating exercise dyspnea, bending-induced dyspnea, fatigue, exercise-induced syncope, and edema. Treatment for pulmonary hypertension is generally symptomatic and varies based on the disease type, severity, and individual patient needs.

• The average age-adjusted PH mortality rate was 7.9 per 100,000 individuals and increased by 1.9% annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: